chalcone has been researched along with Liver Failure, Acute in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, B; Cho, WJ; Han, SB; Hong, JT; Hwang, BY; Jung, SH; Kim, Y; Kwak, JA; Na, CS; Park, SH; Yun, CY | 1 |
| Chai, KY; Guan, LP; Jin, QH; Jin, XJ; Kwak, KC; Nan, JX; Quan, ZS | 1 |
2 other study(ies) available for chalcone and Liver Failure, Acute
| Article | Year |
|---|---|
Piperidylmethyloxychalcone improves immune-mediated acute liver failure via inhibiting TAK1 activity.
Topics: Animals; Chalcone; Disease Models, Animal; Gene Expression Regulation; Hepatocytes; Immune System Diseases; Liver Failure, Acute; Macrophages; MAP Kinase Kinase Kinases; Mice; Models, Molecular; Molecular Conformation; NF-kappa B; Phosphorylation; Protective Agents; Protein Binding; Structure-Activity Relationship | 2017 |
Protective effects of chalcone derivatives for acute liver injury in mice.
Topics: Animals; Chalcone; DNA Fragmentation; Liver; Liver Failure, Acute; Male; Mice; Mice, Inbred C57BL; Protective Agents | 2005 |